Ocular Therapeutix Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Public

  • Employees
  • 325

Employees

  • Stock Symbol
  • OCUL

Stock Symbol

  • Investments
  • 2

  • Share Price
  • $6.21
  • (As of Friday Closing)

Ocular Therapeutix General Information

Description

Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye. The company uses its proprietary hydrogel platform technology to deliver therapeutic agents to the eye. Its pipeline consists of eye medication that aims to overcome the limitations of current eye-drop-based therapies for ophthalmic diseases and conditions. Its pipeline product includes Dextenza, OTX-TIC, OTX-TKI, and OTX-IVT.

Contact Information

Website
www.ocutx.com
Formerly Known As
I-Therapeutix
Ownership Status
Publicly Held
Financing Status
Formerly VC-backed
Corporate Office
  • 15 Crosby Drive
  • Bedford, MA 01730
  • United States
+1 (781)
Primary Industry
Drug Delivery
Other Industries
Therapeutic Devices
Other Pharmaceuticals and Biotechnology
Stock Exchange
NAS
Corporate Office
  • 15 Crosby Drive
  • Bedford, MA 01730
  • United States
+1 (781)

Ocular Therapeutix Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Ocular Therapeutix Stock Performance

As of 13-Nov-2026, Ocular Therapeutix’s stock price is $6.21. Its current market cap is $1.37B with 220M shares.

(As of Friday Closing)

Stock Price Previous Close 52 wk Range Market Cap Shares Average Volume EPS
$6.21 $6.28 $6.00 - $16.44 $1.37B 220M 3.1M -$1.46

Ocular Therapeutix Financials Summary

As of 30-Sep-2026, Ocular Therapeutix has a trailing 12-month revenue of $50.4M.

In Thousands,
USD
TTM 30-Sep-2026 FY 2025 31-Dec-2025 FY 2024 31-Dec-2024 FY 2023 31-Dec-2023
EV 1,165,196 2,318,632 990,541 484,648
Revenue 50,384 51,951 63,723 58,443
EBITDA (332,605) (268,136) (196,425) (70,398)
Net Income (326,811) (265,939) (193,506) (80,736)
Total Assets 605,647 808,057 457,935 252,060
Total Debt 80,013 76,968 75,783 83,389
Public Fundamental Data provided by Morningstar, Inc. disclaimer

Ocular Therapeutix Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Ocular Therapeutix‘s full profile, request access.

Request a free trial

Ocular Therapeutix Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion
Price
% Owned

This information is available in the PitchBook Platform. To explore Ocular Therapeutix‘s full profile, request access.

Request a free trial

Ocular Therapeutix Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Ocular Therapeutix Inc is a biotechnology company that specializes in therapies for diseases and conditions of the eye.
Drug Delivery
Bedford, MA
325 As of 2025

Bagsvaerd, Denmark
 

Alpharetta, GA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Ocular Therapeutix Competitors (6)

One of Ocular Therapeutix’s 6 competitors is Novo Nordisk, a Corporation company based in Bagsvaerd, Denmark.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Novo Nordisk Corporation Bagsvaerd, Denmark
Clearside Biomedical Formerly VC-backed Alpharetta, GA
Mati Therapeutics Venture Capital-Backed Austin, TX
TearClear Venture Capital-Backed Princeton, NJ
iSTAR Medical Formerly VC-backed Wavre, Belgium
To view Ocular Therapeutix’s complete competitors history, request access »

Ocular Therapeutix Patents

Ocular Therapeutix Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026107180-A1 Implant injector device Pending 14-Nov-2024
WO-2026080130-A1 Ocular implant comprising an amorphous solid dispersion comprising a tyrosine kinase inhibitor and a polymer excipient Pending 09-Oct-2024
AU-2025282157-A1 Compositions and methods for treating ocular diseases Pending 06-Jun-2024
WO-2025255203-A1 Compositions and methods for treating ocular diseases Pending 06-Jun-2024
WO-2025255023-A1 Sustained release prodrug implant Pending 03-Jun-2024 A61K9/0051
To view Ocular Therapeutix’s complete patent history, request access »

Ocular Therapeutix Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Ocular Therapeutix Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Ocular Therapeutix‘s full profile, request access.

Request a free trial

Ocular Therapeutix Investments & Acquisitions (2)

Ocular Therapeutix’s most recent deal was a Seed Round with Auto Legends for . The deal was made on 06-Mar-2025.

Company Name Deal Date Deal Type Deal Size Industry Lead Partner
Auto Legends 06-Mar-2025 Seed Round Entertainment Software
InnFocus 01-Mar-2023 Merger/Acquisition Surgical Devices
To view Ocular Therapeutix’s complete investments and acquisitions history, request access »

Ocular Therapeutix ESG

Risk Overview

Risk Rating

Updated November, 04, 2026

35.67 | High Risk

Risk Scale

A lower score indicates better sustainability

Negl

0-10

Low

10-20

Med

20-30

High

30-40

Severe

40+

Exposure

Exposure refers to the extent to which a company is exposed to different material ESG issues

Management

Management is related to actions taken to manage ESG issues

Peers Analysis

Peer performance insights compare the company’s ESG performance to the performance of selected peers to help inform future ESG decisions and drive internal performance improvements.

Global

Covered Companies

of 13,592

Rank

Percentile

Pharmaceuticals

Industry

of 852

Rank

Percentile

Pharmaceuticals

Subindustry

of 354

Rank

Percentile

To view Ocular Therapeutix’s complete esg history, request access »

Ocular Therapeutix Affiliates

Subsidiaries (1)

Name Industry Location Year Founded
Ocular Therapeutix Securities Bedford, MA 2021

Ocular Therapeutix FAQs

  • When was Ocular Therapeutix founded?

    Ocular Therapeutix was founded in 2006.

  • Where is Ocular Therapeutix headquartered?

    Ocular Therapeutix is headquartered in Bedford, MA.

  • What is the size of Ocular Therapeutix?

    Ocular Therapeutix has 325 total employees.

  • What industry is Ocular Therapeutix in?

    Ocular Therapeutix’s primary industry is Drug Delivery.

  • Is Ocular Therapeutix a private or public company?

    Ocular Therapeutix is a Public company.

  • What is Ocular Therapeutix’s stock symbol?

    The ticker symbol for Ocular Therapeutix is OCUL.

  • What is the current stock price of Ocular Therapeutix?

    As of 13-Nov-2026 the stock price of Ocular Therapeutix is $6.21.

  • What is the current market cap of Ocular Therapeutix?

    The current market capitalization of Ocular Therapeutix is $1.37B.

  • What is Ocular Therapeutix’s current revenue?

    The trailing twelve month revenue for Ocular Therapeutix is $50.4M.

  • Who are Ocular Therapeutix’s competitors?

    Novo Nordisk, Clearside Biomedical, Mati Therapeutics, TearClear, and iSTAR Medical are some of the 6 competitors of Ocular Therapeutix.

  • What is Ocular Therapeutix’s annual earnings per share (EPS)?

    Ocular Therapeutix’s EPS for 12 months was -$1.46.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process